Skip to Content
Merck
All Photos(1)

Key Documents

193038

Sigma-Aldrich

Borane dimethyl sulfide complex solution

1.0 M in methylene chloride

Synonym(s):

BMS, Trihydro[thiobis[methane]]boron

Sign Into View Organizational & Contract Pricing


About This Item

Linear Formula:
(CH3)2S · BH3
CAS Number:
Molecular Weight:
75.97
Beilstein:
3663489
MDL number:
UNSPSC Code:
12352112
PubChem Substance ID:

form

liquid

reaction suitability

reagent type: reductant

concentration

1.0 M in methylene chloride

density

1.287 g/mL at 25 °C

storage temp.

2-8°C

SMILES string

B.CSC

InChI

1S/C2H6S.BH3/c1-3-2;/h1-2H3;1H3

InChI key

RMHDLBZYPISZOI-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Application

Reactant used as a regioselective reducing agent

Reactant involved in:
  • Hydroboration / oxidation
Synthesis of cage compounds

Signal Word

Danger

Hazard Classifications

Acute Tox. 4 Oral - Carc. 2 - Eye Dam. 1 - Flam. Liq. 2 - Repr. 1B - Skin Irrit. 2 - STOT SE 3 - Water-react 2

Target Organs

Central nervous system

WGK

WGK 2

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Marieke M ter Wee et al.
Annals of the rheumatic diseases, 74(6), 1233-1240 (2014-05-14)
Recently, we documented the likely non-inferiority of Combinatietherapie Bij Reumatoïde Artritis (COBRA)-light therapy (methotrexate increased to 25 mg/week with initial prednisolone 30 mg/day) compared with the original COBRA therapy (methotrexate 7.5 mg/week, sulfasalazine 2 g/day, with initial prednisolone 60 mg/day) after 26 weeks in patients with
A Burchert et al.
Leukemia, 29(6), 1331-1335 (2015-02-26)
A minority of chronic myeloid leukemia (CML) patients is capable of successfully discontinuing imatinib. Treatment modalities to increase this proportion are currently unknown. Here, we assessed the role of interferon alpha 2a (IFN) on therapy discontinuation in a previously reported
Kathleen C Rollet-Kurhajec et al.
PloS one, 10(6), e0129868-e0129868 (2015-06-20)
In Hepatitis C virus (HCV) mono-infection, male sex is associated with faster liver fibrosis progression but the effects of sex have not been well studied in HIV-HCV co-infected patients. We examined the influence of sex on progression to significant liver
Andrew J Saykin et al.
Alzheimer's & dementia : the journal of the Alzheimer's Association, 11(7), 792-814 (2015-07-22)
Genetic data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) have been crucial in advancing the understanding of Alzheimer's disease (AD) pathophysiology. Here, we provide an update on sample collection, scientific progress and opportunities, conceptual issues, and future plans. Lymphoblastoid cell
Veena K Ranganath et al.
Arthritis care & research, 67(7), 929-939 (2015-01-13)
To evaluate the effect of sustained American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) Boolean remission on residual joint inflammation assessed by magnetic resonance imaging (MRI) and to secondarily evaluate other clinical definitions of remission, within an early seropositive

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service